A long-acting fibronectin, its preparation method and application
By tandemly repeating the FNIII1C amino acid sequence in Saccharomyces cerevisiae and performing site-directed PEG modification, the problems of complex extraction of natural fibronectin and large molecular weight of recombinant FN were solved, and a long-acting fibronectin with high biological activity and stability was prepared. It can be applied to skin care and cosmetic products to promote wound healing and reduce scar formation.
Patent Information
- Application Number
- CN202211719255.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-30
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-12-30
AI Technical Summary
In existing technologies, the extraction of natural fibronectin is complex and costly, and the recombinant FN expressed by genetic engineering has a large molecular weight and its biological activity is affected, making it difficult to apply widely. Furthermore, the immunogenicity and stability issues of existing recombinant FN have not been effectively resolved.
By tandemly repeating the FNIII1C amino acid sequence and expressing fibronectin in Saccharomyces cerevisiae, combined with site-directed PEG modification, the biological activity and molecular weight were improved, while the immunogenicity was reduced.
The efficient preparation of long-acting fibronectin was achieved, which improved its biological activity and stability, reduced its immunogenicity, promoted wound healing and reduced scar formation, and had excellent skin care effects.
Smart Images

Figure CN116003635B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to a long-acting fibronectin, its preparation method, and its applications. Background Technology
[0002] Fibronectin (FN) is a high-molecular-weight glycoprotein and one of the most important components of the extracellular matrix, widely distributed in blood, body fluids, and various tissues. In vertebrates, FN is highly conserved and possesses a similar tissue structure. FN exists as a dimer, composed of two polypeptide chains with a molecular weight of approximately 250 kDa linked by a disulfide bond at the C-terminus. Each chain contains a series of repeating units: 12 type I, 2 type II, and 7 type III repeating units. These repeating units form functional domains that bind to fibrin, collagen, gelatin, bacteria, and cells to perform various biological functions, such as opsonization, phagocytosis, angiogenesis, embryogenesis, tissue remodeling, and reshaping. It also plays an important role in many pathological processes, such as polyarthritis and tumors. Currently, FN is used in emerging biomedical fields, such as oncology, wound healing, antibacterial agents, and tissue engineering materials, and is also beginning to be applied in the field of cosmetics and skincare.
[0003] Currently, free radicals (FNs) are mainly obtained through two pathways: extraction from biological tissues, cells, or body fluids; and the construction of expression vectors using genetic engineering techniques to express recombinant FNs using a host. Natural FN purification processes are complex and costly, and the large molecular weight of the resulting product limits its widespread application. However, expressing exogenous genes using genetic engineering techniques has become one of the most efficient ways to obtain target proteins. Due to the large molecular weight of natural FNs and the low feasibility of expressing the entire sequence, existing methods mainly involve selecting or combining different functional domains of the FN for expression to obtain recombinant FNs with different functions. However, selecting a specific domain for expression reduces the number of binding sites compared to natural proteins, which can negatively impact the protein's biological activity. Summary of the Invention
[0004] To address the aforementioned technical problems, this invention provides a long-acting fibronectin, its preparation method, and its applications. This invention utilizes tandem repetitive expression of the FNIII1C target gene sequence to present more positive binding sites, thereby increasing the protein's biological activity and molecular weight, resulting in a longer-lasting effect. Furthermore, site-directed PEG modification significantly reduces the immunogenicity of the fibronectin.
[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows:
[0006] This invention provides a long-acting fibronectin obtained by tandem repeating the FNIII1C amino acid sequence, the amino acid sequence of which is shown in Seq ID NO.2.
[0007] The present invention also provides a gene encoding the long-acting fibronectin, the nucleotide sequence of which is shown in Seq ID NO.1.
[0008] The present invention also provides an expression vector containing the aforementioned gene.
[0009] Furthermore, the expression vector is *Saccharomyces cerevisiae*.
[0010] The present invention also provides a PEG-modified long-acting fibronectin, which is obtained by PEG modification of the long-acting fibronectin described in the present invention.
[0011] The method for preparing the PEG-modified long-acting fibronectin includes the following steps:
[0012] (1) Add EDC and cystamine to the MES buffer of long-acting fibronectin and react at 4°C for 3 hours;
[0013] (2) Then add TCEP to step (1) to carry out the reduction reaction, and react at 4°C for 2 hours;
[0014] (3) Finally, add methoxy polyethylene glycol maleimide and react at 4°C for 20 hours;
[0015] (4) Purify the resulting reaction solution.
[0016] Furthermore, the molecular weight range of the methoxy polyethylene glycol maleimide is 8-12 kDa.
[0017] The molar ratio of fibronectin, EDC, and cystamine is 1:2:2; the molar ratio of fibronectin and methoxy polyethylene glycol maleimide is 1:4.
[0018] The present invention also provides a method for preparing the long-acting fibronectin, the method comprising the following steps:
[0019] 1) Based on the properties of the pYES2 / CT-MFα vector and the codon preference of Saccharomyces cerevisiae host, the FNIII1C gene sequence was designed. The designed tandem repeat FNIII1C gene sequence is shown in Seq ID NO.1.
[0020] 2) Design amplification primers based on the FNIII1C gene sequence, perform PCR amplification, and then construct a recombinant vector;
[0021] 3) The recombinant vector was added to the competent cells of Saccharomyces cerevisiae INVSC1 and electroporation was performed to obtain engineered bacteria;
[0022] 4) Inducing expression in engineered bacteria;
[0023] 5) After filtration through a microporous membrane, the supernatant after induced expression was purified by nickel ion chelate affinity chromatography to obtain long-acting fibronectin, whose amino acid sequence is shown in Seq ID NO.2;
[0024] 6) Modify the long-acting fibronectin obtained in step 5) with PEG to obtain PEG-modified long-acting fibronectin.
[0025] In step 4), the induction time is 20 h, until the initial OD... 600nm It reached 0.4.
[0026] Finally, this invention also provides the application of the long-acting fibronectin or the PEG-modified long-acting fibronectin in skincare or cosmetic products. The long-acting fibronectin or the PEG-modified long-acting fibronectin, as a raw material for skincare or cosmetic products, has the effects of fading dark spots and repairing skin barrier damage.
[0027] The long-acting fibronectin provided by this invention is obtained through tandem repeats of the FNIII1C amino acid sequence. These repeats consist of three segments, presenting more positive binding sites, which is beneficial for improving the biological activity of fibronectin. Simultaneously, the tandem repetition expression increases the molecular weight of fibronectin, making it more long-lasting. This invention utilizes a Saccharomyces cerevisiae secretory expression system to express fibronectin through gene recombination. Saccharomyces cerevisiae is a recognized safe microorganism in the pharmaceutical and food industries. As a eukaryotic expression system, it can express proteins at high levels and secrete them into the culture medium. The product production process is simple, low-cost, produces a uniform product, and is non-immunogenic.
[0028] The PEG-modified long-acting fibronectin (PEG-rFN) provided by this invention significantly improves the half-life of fibronectin and effectively enhances the stability of recombinant proteins through PEG modification.
[0029] PEGylation is further divided into random modification and site-specific modification. Currently, most FDA-approved PEGylated drugs are products of random modification. Randomly modified proteins often target the ε-NH2 or α-NH2 of lysine residues. Since lysine residues are usually abundant in proteins, this modification results in the modification of multiple lysine residues, yielding a mixture of PEGylated isomers. This invention selects a modification method that modifies the C-terminal carboxyl group of fibronectin to perform PEGylation on the fusion protein FNIII1C. This is a second-generation PEGylation technology developed based on random modification. Through optimization of the modification method, the choice of PEGyl modifier, and the reaction conditions, site-specific modification is achieved. The product obtained by this modification is homogeneous, with fewer isomers, better activity retention, and significantly reduced immunogenicity.
[0030] In vitro experiments have demonstrated that the PEG-rFN provided by this invention can significantly promote cell adhesion and migration. Animal clinical trial data show that, under the premise of a basic treatment regimen, the use of PEG-rFN can promote wound healing and reduce scar formation. Efficacy evaluation results of cosmetics formulated with PEG-rFN on human skin show that it has a repairing effect on facial skin barrier damage. Furthermore, because FN is a biological protein, it has the advantages of easy decomposition and no residue, offering a significant advantage over ordinary chemical cosmetics and hormonal drugs in that it has no side effects. Attached Figure Description
[0031] Figure 1 shows the pYES2 / CT-MFα vector map;
[0032] Figure 2 The results of enzyme digestion of plasmid pUC57-FNIII1C are shown. M: DL2000 DNA Marker; 1-2: double digestion of pUC57-FNIII1C plasmid; 3: negative control.
[0033] Figure 3 The results of bacterial culture PCR identification of the pYES2 / CT-MFα-FNIII1C vector are shown. M: DL2000 DNA Marker; 1-4: Bacterial culture PCR results.
[0034] Figure 4 SDS-PAGE identification results of the supernatant induced by INVSC1 / pYES2 / CT-MFα-FNIII1C expression: M: Marker; 1: Induction supernatant; 2: Plasmid empty vector induction supernatant.
[0035] Figure 5 SDS-PAGE identification results of PEG-modified long-acting rFN and purified, M: Marker; 1: Purified PEG-rFN;
[0036] Figure 6 The results of cell adhesion promotion for PEG-rFN (a), rhFN (b), and negative control (c) are shown.
[0037] Figure 7 Fitting results of data calculated for cell adhesion promotion results of rhFN(a) and PEG-rFN(b);
[0038] Figure 8 Image showing the results of the cell scratch assay after 18 hours;
[0039] Figure 9 The image shows the wound healing status of rabbits in the experimental group on the 10th day after surgery. Detailed Implementation
[0040] The present invention will now be described in detail with reference to the embodiments.
[0041] Example 1
[0042] A method for preparing long-acting fibronectin includes the following steps:
[0043] 1) Based on the properties of the pYES2 / CT-MFα carrier (e.g.) Figure 1 Based on the host codon preference of Saccharomyces cerevisiae (as shown in the image) and the nucleotide sequence of the FNIII1C gene, as shown in Seq ID NO.1, the specific sequence is as follows:
[0044] CGCCGGCGC TCAGATAAAATTATCCATCTTACAGATGATTCATTTGACACGGACGTACTAAAA AACGC CCCCCAGCCCAGCCACATCAGCAAGTACATCCTGAGGTGGAGGCCCAAGAACAGCGTGGGCAGGTGGAAGGAGGCC ACCATCCCCGGCCACCTGAACAGCTACACCATCAAGGGCCTGAAGCCCGGCGTGGTGTACGAGGGCCAGCTGATCA GCATCCAGCAGTACGGCCACCAGGAGGTGACCAGGTTCGACTTCACCACCACCAGCACCAGCACCCCCAACGCCCC CCAGCCCAGCCACATCAGCAAGTACATCCTGAGGTGGAGGCCCAAGAACAGCGTGGGCAGGTGGAAGGAGGCCACC ATCCCCGGCCACCTGAACAGCTACACCATCAAGGGCCTGAAGCCCGGCGTGGTGTACGAGGGCCAGCTGATCAGCA TCCAGCAGTACGGCCACCAGGAGGTGACCAGGTTCGACTTCACCACCACCAGCACCAGCACCCCCAACGCCCCCCA GCCCAGCCACATCAGCAAGTACATCCTGAGGTGGAGGCCCAAGAACAGCGTGGGCAGGTGGAAGGAGGCCACCATC CCCGGCCACCTGAACAGCTACACCATCAAGGGCCTGAAGCCCGGCGTGGTGTACGAGGGCCAGCTGATCAGCATCC AGCAGTACGGCCACCAGGAGGTGACCAGGTTCGACTTCACCACCACCAGCACCAGCACCCCC CACCATCATCATCACCAC.
[0045] The amino acid sequence of the FNIII1C protein encoded by the above-mentioned gene is shown in Seq ID NO.2, specifically as follows:
[0046] RRRSDKIIHLTDDSFDTDVLK NAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVY EGQLISIQQYGHQEVTRFDFTTTSTSTPNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYE GQLISIQQYGHQEVTRFDFTTTSTSTPNAPQPSHISKYILRWRPKNSVGRWKEATI PGHLNSYTIK GLKPGVVYEG QLISIQQYGH QEVTRFDFTT TSTSTP HHHHHH;
[0047] Among them, NAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTP is a repeating FNIII1C amino acid sequence, which is the amino acid sequence of the target gene.
[0048] 2) The optimized FNIII1C protein gene sequence was sent to General Biotech for the artificial synthesis of pUC57-FNIII1C, and detection primers were synthesized simultaneously.
[0049] T7: 5'-TAATACGACTCACTATAGGG-3', as shown in Seq ID NO.3;
[0050] CYC1 Terminator: 5'-GTGACATAACTAATTACATGATG-3', as shown in Seq ID NO.4.
[0051] 3) Extraction of DH5α / pYES2 / CT-Mfα plasmid
[0052] The plasmid pYES2 / CT-Mfα and the artificially synthesized pUC57-FNIII1C plasmid were double-digested with Not I and Xba I, respectively. The digestion system (50 μL) consisted of 5 μL each of QuickCut Not I and QuickCut Xba I, 35 μL of pYES2 or PCR product, and 5 μL of purified water. Digestion was performed in a 37 °C metal bath for 3 h. After digestion, electrophoresis was performed on a 1.2% agarose gel, as shown in Figure 2, and the double-digested PCR product and plasmid were recovered from the gel.
[0053] The target gene product recovered after double enzyme digestion was ligated with the pYES2 / CT-MFα plasmid using T4 DNA ligase at 16 °C for 1–5 h. The ligation system (10 μL) consisted of 5 μL of the target gene, 3 μL of the vector fragment, 1 μL each of T4 DNA ligase and 10× ligase buffer. The recombinant plasmid was transformed into E. coli DH5α competent cells. After antibiotic selection, positive transformants were picked and cultured. The results of bacterial culture PCR identification are shown below. Figure 3 As shown, after PCR identification, the sample was sent to the company for sequencing. If the sequencing results were correct, the pYES2 / CT-MFα-FNIII1C vector was successfully constructed.
[0054] 4) pYES2 / CT-MFα-FNIII1C was electroporated into Saccharomyces cerevisiae INVSC1 competent cells.
[0055] Add 10 μL of pYES2 / CT-MFα-FNIII1C plasmid to 80 μL of *Saccharomyces cerevisiae* INVSC1 competent cells, mix thoroughly by pipetting and aspiration, and then transfer to a pre-chilled electroporation cuvette. Incubate on ice for 5 min and wipe the outer wall of the cuvette dry. Set the Bio-Rad electroporator to the fungal setting and place the cuvette on the Bio-Rad electroporator for electroporation. Quickly add 500 μL of pre-chilled 1M sorbitol solution to the cuvette, mix thoroughly, and spread onto an SC-U solid plate. Incubate at 30 °C inverted until single colonies grow. Pick transformants and inoculate them into SC-U liquid medium, incubate at 30 °C and 200 rpm. Perform PCR using the bacterial culture as a template to identify and screen positive clones. Select the correctly identified transformants for the next step, thus obtaining the engineered strain INVSC1 / pYES2 / CT-MFα-FNIII1C.
[0056] 5) Inducible expression of INVSC1 / pYES2 / CT-MFα-FNIII1C engineered bacteria
[0057] A single colony of INVSC1 / pYES2 / CT-MFα-FNIII1C was picked and inoculated into 20 mL of SC-U selective medium, and cultured overnight at 30°C with shaking at 220 rpm. Its OD value was then measured. 600nm Calculate the absorbance value, and then transfer the corresponding volume of bacterial culture to 100 mL of SC-U induction medium to achieve the initial OD value. 600nm The value reached 0.4, and the induction time was 20 h.
[0058] The supernatant of INVSc1 / pYES2 / CT-MFα-FNIII1C induced expression showed a specific band of approximately 28 kDa after SDS-PAGE electrophoresis, while the supernatant of Saccharomyces cerevisiae strains containing the empty pYES2 / CT-MFα vector did not show a specific band. Figure 4 As shown.
[0059] 6) rFN purification
[0060] The culture supernatant was collected by centrifugation and filtered through a 0.22 μm filter membrane for use as the sample. A column was self-packed using GE Healthcare's Chelating Sepharose™ Fast Flow nickel ion chelate affinity chromatography packing material. The Ni was washed with 3 column volumes of purified water. 2+ Chelate the affinity chromatography column and then equilibrate with 2-3 column volumes of PBS. Monitor the conductivity and absorbance at 280 nm online. Once both are stable, begin sample loading, setting the flow rate through the column to 5-6 mL / min. Then, pass the sample through the column again with PBS to wash away any unbound proteins until the OD value is reached. 280nm Stable. Then pass the column through a chromatography column with 500 mM imidazole PBS buffer, perform gradient elution and collect the proteins corresponding to the elution peaks to obtain the long-acting fibronectin (long-acting rFN) protein stock solution.
[0061] Example 2
[0062] A method for preparing PEG-modified long-acting fibronectin includes the following steps:
[0063] (1) The protein stock solution prepared in Example 1 was added to 0.05 mol / L pH 5.5 MES buffer, and then EDC and cystamine at 2 times the concentration of the protein stock solution were added and reacted at 4°C for 3 hours, wherein the molar ratio of EDC and cystamine was 1:1.
[0064] (2) Then add 50 mmol / L TCEP to carry out the reduction reaction. The molar ratio of TCEP to cystamine is 1:1. The reaction is carried out at 4°C for 2 hours.
[0065] (3) Finally, mPEG-MAL with a molecular weight of 10 kDa was added to the reaction system. The molar ratio of mPEG-MAL to rFN protein (based on protein content) was 4:1, and the reaction was carried out at 4°C for 20 hours. That is, mPEG was site-modified onto the C-terminal carboxyl group of fibronectin.
[0066] (4) The modified product from step (3) was separated using DEAE Sepharose FF chromatography medium. The modified reaction solution was diluted 5 times with pH 6.5, 10 mmol / L phosphate buffer before loading. The equilibration buffer was also phosphate buffer. Elution was performed using a linear gradient of 0.1-0.3 mol / L NaCl for 5 CV at a flow rate of 5.0 mL / min and a detection wavelength of 280 nm. The elution peak was collected, and the modified PEG-rFN protein was obtained after ultrafiltration, desalting, and concentration. The purity of the sample was detected by SDS-PAGE, and the results are shown in [Figure number missing]. Figure 5 The molecular weight of the PEG modifier used in the modification reaction is 10 kDa, and the molecular weight of the long-acting rFN protein is 28 kDa. Therefore, it can be inferred that the newly appearing band of about 38 kDa is the PEGylated long-acting recombinant human fibronectin. Moreover, one recombinant fibronectin molecule is linked to one PEG chain, indicating that mPEG only modifies the C-terminal carboxyl group of fibronectin.
[0067] Example 3
[0068] Pharmacokinetic study of long-acting fibronectin
[0069] 1) Test sample
[0070] (1) rhFN: Recombinant fibronectin solution, produced according to the method in the applicant's patent CN114557908A;
[0071] (2) Long-acting rFN: Prepared in Example 1;
[0072] (3) PEG-rFN: Prepared in Example 2.
[0073] 2) Test Results
[0074] Pharmacokinetic studies were conducted in rabbits by intramuscular injection of the same doses of rhFN, long-acting rFN, and PEG-rFN. The results showed that the pharmacokinetic characteristics of the three recombinant fibronectins after intramuscular injection conformed to a one-compartment open pharmacokinetic model, exhibiting first-order elimination kinetics. The results are shown in Table 1. The results also showed that, in Example 1, tandem expression of the target gene sequence prolonged the half-life of the recombinant fibronectin, and in Example 2, the half-life of the long-acting rFN, after PEG modification, was further significantly prolonged.
[0075] Table 1. Pharmacokinetic results of three recombinant fibronectins
[0076]
[0077] Example 4
[0078] Stability test of long-acting fibronectin
[0079] Long-acting recombinant fibronectin was obtained through heterologous expression, but long-acting fibronectin suffers from poor thermal stability, which hinders its use and product promotion. Therefore, long-acting rFN was modified by PEG to enhance thermal stability without affecting its biological activity.
[0080] The PEG-rFN obtained in Example 2 and the long-acting rFN obtained in Example 1 were both diluted to 1 mg / mL with 20 mM PBS and dispensed into 5 mL vials, 2 mL per vial. The vials were placed in a constant temperature and humidity incubator at 55°C for accelerated degradation experiments. Samples were taken out at 4 h, 8 h, 12 h, 24 h, 3 d, 5 d, 15 d and 30 d to detect their MDBK cell adhesion-promoting activity. The detection method is described in Example 5.
[0081] Results: As shown in Table 2, in the accelerated degradation test at 55℃, the activity of non-long-acting rhFN was basically degraded within 2 hours. The cell adhesion-promoting activity of unmodified long-acting rFN decreased by more than 30 times after heating for 4 hours and disappeared after heating for 8 hours. However, the cell adhesion-promoting activity of PEG-rFN decreased by less than 20% after heating at 55℃ for 30 days. This indicates that PEG-modified long-acting rFN has higher biological activity than unmodified long-acting rFN.
[0082] Table 2. Results of thermal stability test (unit: U / mg)
[0083]
[0084] Example 5
[0085] Experimental study on the effect of long-acting fibronectin on cell adhesion
[0086] 1) Experimental Principle
[0087] Fibronectin (FN) plays a crucial role in promoting cell adhesion and aggregation, increasing cell adhesion rate and confluence rate, shortening cell confluence time, resulting in better cell morphology and structure, enhanced metabolic rate, and significantly increased protein synthesis. Cell adhesion and aggregation are essential for cell repair and growth; therefore, fibronectin possesses cell-repair-promoting effects. This experiment used a bovine kidney cell (MDBK cell) adhesion assay to count the number of cells in each well at different FN concentrations. The adhesion-promoting activity titer of fibronectin was determined using a four-parameter fitting method.
[0088] 2) Test materials
[0089] 2.1 Main instruments: Clean bench, cell culture incubator.
[0090] 2.2 Reagent Preparation
[0091] Complete cell culture medium: Measure 10 mL of fetal bovine serum and 1 mL of penicillin-drug antibody, add 90 mL of DMEM culture medium, and store at 4°C.
[0092] Serum-free culture medium: Measure 1 mL of the double antibody and add 99 mL of 1640 culture medium, and store at 4℃.
[0093] Digestive fluid: 0.25% trypsin.
[0094] PBS buffer: Weigh 8.0g sodium chloride, 0.20g potassium chloride, 1.44g disodium hydrogen phosphate, and 0.24g potassium dihydrogen phosphate, dissolve in water and bring the volume to 1000mL, then autoclave at 121℃ for 15 minutes.
[0095] 2.3 Cells
[0096] MDBK cells grow in a monolayer and adherent state in complete cell culture medium. They are passaged every 4-5 days, digested and passaged at a 1:2 ratio, and grow and multiply in complete culture medium.
[0097] 2.4 Test sample: PEG-rFN prepared in Example 2.
[0098] 2.5 Positive control: Recombinant fibronectin solution (rhFN), produced according to the method in the applicant's patent CN114557908A.
[0099] 2.6 Negative control: PBS.
[0100] 3) Experimental Operation
[0101] 3.1 Sample dilution and incubation
[0102] Pre-dilute PEG-rFN to 0.5 μg / mL with PBS. After pre-dilution, perform 2-fold serial dilutions in a 96-well plate for a total of 10 dilutions. Use 50 μL of PEG-rFN sample of different dilutions in each well. Set up positive control wells and negative control wells (without PEG-rFN) for serial dilution. Add 50 μL of PBS as a control and incubate overnight at 4°C.
[0103] 3.2 Cell adhesion promotion assay
[0104] After incubation, discard the liquid in the plate, add 100 μL of 30 g / L BSA to each well for blocking, and incubate at 37°C for 1 h. Remove the plate, discard the liquid, and add MDBK cell suspension (resuspended in serum-free medium) at a seeding density of 1.0 × 10⁶ cells / well. 5 Inoculate 100 μL per well at a density of 100 μL per cell / mL and incubate for 5 h.
[0105] 3.3 Results Observation and Calculation
[0106] Wash the incubated cell plate three times with PBS and observe cell adhesion under a microscope. Figure 6 As shown, five points were selected under a 200x microscope (excluding the edge) to count the number of adherent cells. The titer was obtained by fitting a four-parameter curve based on the counting results.
[0107] The following are examples of calculation results, and the fitting results are as follows: Figure 7 As shown:
[0108] Table 3 Cell count at five points in each well of the plate
[0109]
[0110] Table 4 Valence Statistics
[0111]
[0112] according to Figure 6 The results in Table 4 show that the specific activity of PEG-rFN in promoting cell adhesion (cell fixation) is significantly higher than that of rhFN.
[0113] Example 6
[0114] Cell scratch assay of long-acting fibronectin
[0115] 1) Experimental Principle
[0116] When cells grow to the point of fusing into a monolayer, a blank area, called a "scratch," is artificially created on the fused monolayer. Cells at the edge of the scratch gradually move into the blank area, causing the scratch to heal. Images are captured at the beginning and periodically during cell migration, and the migration rate is determined by comparing the images.
[0117] 2) Experimental materials
[0118] 2.1 Main instruments: Clean bench, cell culture incubator.
[0119] 2.2 MDBK cells; serum-free cell culture medium.
[0120] 2.3 Sample: PEG-rFN prepared in Example 2.
[0121] 2.4 Positive control: Recombinant fibronectin solution (rhFN), produced according to the method in the applicant's patent CN114557908A, batch number 2021003.
[0122] 3) Experimental Procedure
[0123] 3.1 First, use a marker pen to draw horizontal lines evenly on the back of the 6-hole plate, aligning with a ruler, with each line approximately every 0.5 to 1 cm, passing through the holes.
[0124] 3.2 Add a concentration of 5×10 to the wells of a 6-well plate. 5 2 mL of MDBK cell suspension per cell / mL.
[0125] 3.3 On the second day, it was observed that the cells in the 6-well plate were all fully grown in a monolayer. Using a pipette tip as a guide, two lines were made perpendicular to the horizontal line on the back of the plate.
[0126] 3.4 Wash the cells three times with PBS to remove any suspended cells that have been swept off.
[0127] 3.5 Add 1.8 mL of serum-free culture medium to each well according to the grouping, then add 200 μL of PEG-rFN and positive control rhFN respectively, and add an equal volume of PBS solution to the cell control well.
[0128] 3.6 Place in a 37°C, 5% CO2 incubator and incubate. Take a photo at 0°C and record the location of the photo in each well. Observe and photograph the fixed locations during subsequent observations.
[0129] 4) Experimental Results
[0130] The results of cell control wells and sample wells observed at 0h and 18h are as follows: Figure 8 As shown (the arrows in the image indicate the distance of the scratches).
[0131] Figure 8 The results in Table 5 show that, 18 hours after loading the PBS control wells, the cells were in normal condition and the scratched area had shrunk by 40.34%; similarly, 18 hours after loading the rhFN positive control wells, the cells were in normal condition and the scratched area had shrunk by 62.67%; and 18 hours after loading the PEG-rFN sample wells, the cells were in normal condition and the scratched area had shrunk by 82.89%, which was significantly higher than that of the PBS control group and the rhFN positive control group.
[0132] Table 5. Cell migration rate results
[0133]
[0134] Example 7
[0135] Experiment on wound repair in rabbits with long-acting fibronectin modified by site-specific PEGylation
[0136] Using experimental rabbits, after creating a skin injury model on their backs, the PEG-rFN protein was applied by smearing to verify the wound repair function of PEG-rFN.
[0137] 1) Experimental materials
[0138] 1.1 Experimental animals 6 conventional-grade New Zealand rabbits, 3-4 months old, weighing 2.0~2.5kg, were purchased from the Laboratory Animal Center of Anhui Medical University, with the license number: SYXK (Wan) 2011-007.
[0139] 1.2 Sample PEG-rFN, with a dosage of 0.1mg / kg, administered once every 3 days.
[0140] 2) Experimental methods
[0141] 2.1 Establishment of skin injury model
[0142] To verify the promoting effect of PEG-rFN on wound healing, it is necessary to establish a skin injury model. Referring to the description of skin injury degree in Appendix "3. Skin Irritation Test" of the "Technical Guidelines for the Study of Drug Irritation, Hypersensitivity and Hemolysis" promulgated on May 13, 2014, that is, "the degree of skin injury in the damaged skin test is limited to damage to the epidermal layer", so the sandpaper polishing method was selected in this experiment.
[0143] After the rabbits were anesthetized with ether, the hair on their backs was removed as completely as possible using a pet electric clipper. The 6 rabbits were divided into 2 groups, 3 in each group. The sandpaper was wrapped around a wooden stick, and then gently rubbed on the skin surface of the rabbits until the skin surface became light red, so as to establish a back skin injury model of the rabbits.
[0144] 2.2 Treatment
[0145] The two groups of rabbits were divided into an experimental group and a control group, and the wound surfaces were smeared with the sample and normal saline respectively, wherein the dosage of normal saline was 2mL per rabbit. Every 3 days, the wound was disinfected and cleaned before applying the corresponding drug, and then covered and bandaged with sterile gauze. The wound healing was observed daily.
[0146] 3) Experimental results
[0147] The wounds of the animals in the experimental group had all healed on the 10th day, as Figure 9As shown in Table 6, the average healing time was 9.7 days. No wound infection or edema was observed during the healing process. Mild redness and swelling were present in the early stages of healing, and no obvious scarring occurred at the wound site after healing. In the control group, two animals still had not fully healed by day 10. During this period, no wound infection was observed. Significant redness and swelling and mild edema were present in the early stages of healing, and scab formation and obvious scarring appeared on the local wound in the later stages.
[0148] Table 6 Average wound healing timeline
[0149]
[0150] Example 8
[0151] Efficacy evaluation of PEG-modified long-acting fibronectin in human skin
[0152] 1) The cosmetics formulated with the PEG-rFN product prepared in Example 2 were tested by a third-party laboratory. The patch test showed that the PEG-rFN product prepared in Example 2 had no adverse skin reactions.
[0153] 1.1 Patch test method: Select a qualified patch tester and use the closed patch test method. Apply 0.020~0.025mL of the sample into the patch tester. Remove the test substance after 24 hours. Observe the skin reaction at 0.5, 24 and 48 hours after removal. Record the results according to the skin reaction grading standard in the "Cosmetic Safety Technical Specifications" (2015 edition), as shown in Table 7.
[0154] Table 7. Grading Criteria for Skin Reaction in Skin Occlusive Patch Tests
[0155]
[0156] 1.2 Test Results
[0157] Table 8 Results of Cosmetic Human Skin Patch Test
[0158]
[0159] 2) Efficacy evaluation on human skin: The cosmetic formulated with the PEG-rFN product prepared in Example 2 has a repairing effect on facial skin barrier damage.
[0160] 2.1 Test Objective
[0161] Asian adult subjects used the test sample (containing PEG-rFN) for 28 consecutive days under normal conditions. The moisture content of the stratum corneum and the transepidermal water loss (TEWL) value of the skin were measured by the instrument probe to evaluate the moisturizing and repairing efficacy of the test sample.
[0162] 2.2 Test Results
[0163] Table 9
[0164]
[0165] 2.3 Test Conclusion
[0166] Thirty-three Asian adult subjects aged 24 to 54 years used the test sample (containing PEG-rFN) for 28 consecutive days under normal conditions. The moisture content of the stratum corneum and the transepidermal water loss (TEWL) value of the skin were measured by the instrument probe. The results showed that the test sample had moisturizing and repairing effects after 28 days of use.
[0167] The above detailed description of a long-acting fibronectin, its preparation method, and its application, with reference to the embodiments, is illustrative rather than limiting. Several embodiments may be listed within the defined scope. Therefore, variations and modifications that do not depart from the overall concept of the present invention should be within the protection scope of the present invention.
Claims
1. A long-acting fibronectin, characterized in that, The amino acid sequence of the long-acting fibronectin was obtained by tandem repeating the FNIII1C amino acid sequence, as shown in Seq ID NO.
2.
2. A gene encoding the long-acting fibronectin as described in claim 1, characterized in that, The nucleotide sequence of the gene is shown in Seq ID NO.
1.
3. An expression vector containing the gene as described in claim 2.
4. A PEG-modified long-acting fibronectin, characterized in that, The long-acting fibronectin of claim 1 was obtained by PEG modification; the PEG modification used was methoxy polyethylene glycol maleimide with a molecular weight of 10 kDa.
5. The method for preparing long-acting fibronectin as described in claim 1, characterized in that, The preparation method includes the following steps: 1) Based on the properties of the pYES2 / CT-MFα vector and the codon preference of Saccharomyces cerevisiae host, the FNIII1C gene sequence was designed. The designed tandem repeat FNIII1C gene sequence is shown in Seq ID NO.
1. 2) Design amplification primers based on the FNIII1C gene sequence, perform PCR amplification, and then construct a recombinant vector; 3) The recombinant vector was added to the competent cells of Saccharomyces cerevisiae INVSC1 and electroporation was performed to obtain engineered bacteria; 4) Inducing expression in engineered bacteria; 5) After filtration through a microporous membrane, the supernatant of the induced expression solution is purified by nickel ion chelate affinity chromatography to obtain long-acting fibronectin.
6. The preparation method according to claim 5, characterized in that, The long-acting fibronectin has a molecular weight of 28 kDa.
7. The use of the long-acting fibronectin as described in claim 1 or the PEG-modified long-acting fibronectin as described in claim 4 in the preparation of skin care products.
8. The use of the long-acting fibronectin as described in claim 1 or the PEG-modified long-acting fibronectin as described in claim 4 in the preparation of cosmetics.
Citation Information
Patent Citations
Fibroneclastin composition freeze-dried micro-core with skin barrier repairing effect and preparation method thereof
CN114557908A
Recombinant human fibronectin III1-C, and preparation method and application thereof
CN111217903A
Self-fused concatenation protein modification method and application thereof
CN113735980A
